ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial.Patrice Carde, Nicolas Mounier, Matthias Karrasch et al.|Journal of Clinical Oncology|2012Cited by 50
Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN studyFrancesc Bosch, Véronique Leblond, Mourad Tiab et al.|Leukemia|2019Cited by 12